New Approval Strengthens Top Spot For AstraZeneca's Tagrisso

Gets EU Nod for Early-Stage NSCLC

 
• By Kevin Grogan

Competition may be on the horizon but Tagrisso's position as standard of care for EGFR-mutated NSCLC looks solid, not least after a thumbs-up in the EU for the adjuvant treatment of adults with early-stage disease.

Sodertalje, Sweden - April 27, 2014: Three purple flags with the logo for Atrazeneca flying in the wind on top of the flagpoles against the blue sky.
Tagrisso flying high as AstraZeneca's biggest seller • Source: Archive

More from New Products

More from Scrip